Cowen analyst Eric Schmidt is out today with a research note on shares of bluebird bio Inc (NASDAQ:BLUE), following updated data from the company’s Phase …
bluebird bio Inc (NASDAQ:BLUE) and apceth Biopharma announced today that they have entered into a strategic manufacturing agreement providing for the future European …
bluebird bio Inc (NASDAQ: BLUE) announced treatment of the first patient in Northstar-2, the Phase 3 study of its LentiGlobin drug product in …
During last week’s American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, bluebird bio Inc (NASDAQ:BLUE) provided clinical updates on …
bluebird bio Inc (NASDAQ:BLUE) announced the pricing of an underwritten public offering of 3,289,473 shares of its common stock at a public offering …
bluebird bio Inc (NASDAQ:BLUE) announced that it has commenced an underwritten public offering of $200 million of its common stock. bluebird bio also …
bluebird bio Inc (NASDAQ:BLUE) just announced Phase 1 results of bb2121, the BCMA CAR-T therapy, in patients with relapsed /refractory multiple myeloma that …
bluebird bio Inc (NASDAQ:BLUE) announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief …
The biotech-verse is in full upheaval mode as Heat Biologics Inc (NASDAQ:HTBX) shares nosedive following disheartening Phase II results in bladder cancer and …
bluebird bio Inc (NASDAQ:BLUE) shares are surging 25% after releasing interim results from the firm’s Phase 1 trial of its anti-BCMA CAR T …